Figure 5
From: MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma
HMGA2 overexpression in uterine leiomyomas. (a) Photomicrographs illustrate examples of strong and diffuse immunoreactivity for HMGA2 in uterine leiomyomas. High grade serous ovarian carcinoma was used as the positive control (left upper). (b) and (c) Dot-plot analysis of distribution of MED12 mutations and HMGA2 overexpression in 178 cases of uterine leiomyomas. Seventy-four percent of leiomyomas have MED12 mutations and lack of HMGA2 overexpression; 10% of leiomyomas have wild type MED12 and HMGA2 overexpression; and remainder 16% of leiomyomas have wild type MED12 and lack of HMGA2 overexpression.
